BioCentury
ARTICLE | Clinical News

Nanoplatin: Phase III ongoing

June 29, 2015 7:00 AM UTC

NanoCarrier said it submitted an IND in Japan to add Japanese patients to an ongoing, open-label, Asian Phase III trial comparing 90 mg/m 2 IV Nanoplatin given every 3 weeks plus gemcitabine vs. gemci...